Annual Reports in Medicinal Chemistry

New Approaches in Conjugate Drug Design: Part 1
Erscheinungsjahr 2026
ISBN: 978-0-443-47262-6
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

New Approaches in Conjugate Drug Design: Part 1, published as Volume 67 of the serial Annual Reports in Medicinal Chemistry, provides a comprehensive overview of current strategies in the design and application of drug conjugates. Chapters cover small molecule drug conjugates, antibody-to-small molecule carrier approaches, antibiotic-derived and terpene-derived antimicrobial conjugates, aptamer-RNA conjugates, and phenolic and metal natural product conjugates. Applications span anticancer, antiviral, antifungal, and theranostic therapies, including photoactivatable therapy and emerging approaches in quantum oncology. The volume serves as a reference on design principles, therapeutic applications, and clinical progress in conjugate-based drug discovery.

Autoren/Hrsg.

Weitere Mitwirkende

Seley-Radtke, Katherine

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Organische Chemie

Inhaltsverzeichnis

- From Antibody to Small Molecule Carriers: Targeted Conjugation Under Prodrug Constraints
- Small Molecule Drug Conjugates: Design Principles, Therapeutic Applications, and Clinical Progress
- Antibiotic-Derived Conjugates
- Small-Molecule Drug Conjugates in Anticancer Drug Discovery: Design Strategies, Molecular Hybridization, and Therapeutic Applications
- Aptamer-RNA Conjugates for Precision Medicine: Design Principles, Therapeutic Applications, and Future Perspectives
- Architecting Small Molecule–Drug Conjugates for the Future of Theranostic and Combinatorial Oncology
- Small Molecule Drug Conjugates: Current Progress and Future Directions Toward Precision Therapeutics (2026–2035)
- Small-Molecule Drug Conjugates as a Novel Strategy Against Emerging Respiratory Viruses, Such as Influenza Viruses and SARS-CoV-2
- Small Molecule Drug Conjugates
- Phenolic Small Molecules and Their Conjugates for Antiviral, Antioxidant, and Immunomodulatory Drug Development
- Beyond Ergosterol and the Cell Wall: New Directions in Antifungal Drug Discovery
- Quantum Oncology
- Metal Natural Product Complexes as Emerging Anticancer Chemoimmunotherapeutic Agents
- Terpene-Derived Antimicrobial Hybrids and Conjugates: Design, Synthesis, and Structure-Activity Relationships
- Medicinal Chemistry of IR700-Silicon Phthalocyanine Based Photoactivatable Therapy

Über Autor(innen)

Seley-Radtke, Katherine
Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to
nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic
emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently
used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as
the Program Director for UMBC’s Chemistry-Biology Interface graduate training program
funded by NIH since 2007. This program promotes hands on cross disciplinary research for
almost 50 PhD students from four departments at UMBC and UMB. She is currently the
Immediate Past President and Secretary-Elect for the International Society of Nucleosides,
Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral
Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections
and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,
Molecules – Chemical Biology, and Current Protocols in Chemical Biology.